AIM V® Serum Free Medium
 |
|
Superior Performance, No Serum Required
AIM V® Medium does not require human serum for optimal growth and activation of differentiated lymphoid cells.
- Minimizes risk of viral immunogenicity associated with human serum
- Contains no added cytokines and lymphokines
- All proteins in the formulation have the natural human sequence
AIM V® Versus Human Serum Supplemented Medium
Figure 1 compares relative LAK cell lytic activity of lymphocytes maintained in AIMV® medium with lymphocytes maintained in RPMI-1640 supplemented with serum.
 | Figure 1: Comparison of LAK cell lytic activity: AIM V® Medium versus human serum-supplemented medium. Human peripheral blood lymphocytes (PBLs) were cultured in RPMI-1640 with 1,000 units/mL of IL-2 plus 2% human serum type AB. Human PBLs were also cultured in serum-free AIM V® Medium with 600 units/mL of IL-2. Results are expressed as averages of duplicate flasks assayed in triplicate using Daudi cells as targets. |
Applications of AIM V® Medium
AIM V® Medium has been tested for broad range of applications in adoptive immunotherapy and cellular immunology research. See some of the applications here:
| LAK cell induction & function | Cytokine & antibody effects on LAK cell induction |
| Immunotherapy of murine hepatic metastases | Lymphocyte receptor studies |
| TIL cell generation in hollow fiber bioreactors | NK cells & NK-like effector populations |
| T cell activation | In vitro & in vivo model systems for adoptive immunotherapy |
| Cytokine regulation of effector cells | HIV research |
| Cytokine receptor & postreceptor events in lymphoid effector cells | Macrophage activation |
| Hybridoma growth & monoclonal antibody production | Antibody-dependent cellular cytotoxicity |
| Effector cells in antitumor immunity | Long-term cultivation of functional human macrophages |
| In vitro studies of lymphokines & antibodies | Mechanisms of cell-mediated cytotoxicity |
Cells Types Grown Using AIM V® Medium
| Other cell types
|
${comergentUrl}
